Takeda receives FDA approval to manufacture FLEXBUMIN at new Covington facility

Takeda Pharmaceutical Company received U.S. FDA approval for its new plasma manufacturing facility near Covington, Georgia to produce FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution. The facility had previously received FDA approval for GAMMAGARD LIQUID in June 2018.

“Takeda today announced that the United States Food and Drug Administration (FDA) has approved the company’s second submission for its new plasma manufacturing facility near Covington, Georgia for the production of FLEXBUMIN 25%.”biospace.com

• 1 source
• biospace.comTakeda Receives U.S. FDA Approval to Manufacture FLEXBUMIN® at New Plasma Manufacturing Facility near Covington, Georgia - BioSpaceAnnalee ArmstrongMar 18, 2019

Summarized from public sources; check the original articles before acting on it.